Quest Diagnostics Inc (N:DGX)

Business Focus: Healthcare Facilities & Services

Apr 23, 2024 06:45 am ET
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
First quarter revenues of $2.37 billion, up 1.5% from 2023First quarter reported diluted earnings per share ("EPS") of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with 2023Full year 2024 revenues now expected to be between $9.40 billion and $9.48 billion; reported diluted EPS now expected to be between $7.57 and $7.82; and adjusted diluted EPS expected to be between $8.72 and $8.97SECAUCUS, N.J., April 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the fi
Apr 22, 2024 07:53 am ET
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Company's AD-Detect™ Portfolio Offers AB 42/40 and Other Plasma Biomarker Testing, Alongside Traditional Cerebrospinal Fluid and Genetic Tests, to Provide Robust Offering in Brain Health
Apr 15, 2024 09:15 am ET
Q4HE Initiative Recognized for Efforts To Reduce Health Disparities
NORTHAMPTON, MA / ACCESSWIRE / April 15, 2024 / Quest for Health Equity (Q4HE) was recently honored by the Y in Central Maryland for its grant funding of health equity coalition efforts at the Y in Druid Hill.
Apr 09, 2024 12:00 pm ET
My Quest Story - Jessica Clow
NORTHAMPTON, MA / ACCESSWIRE / April 9, 2024 / Quest Diagnostics:
Apr 02, 2024 07:57 am ET
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
Aim to demonstrate whole genome sequencing can replace the standard diagnostic cascade, for potentially faster diagnosis and lower costs
Apr 01, 2024 02:30 pm ET
My Quest Story - Pauline Chaves
NORTHAMPTON, MA / ACCESSWIRE / April 1, 2024 / Quest Diagnostics
Mar 26, 2024 12:30 pm ET
She Is Not Skipping a Beat, and Patients Are Noticing
NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Quest Diagnostics
Mar 26, 2024 07:09 am ET
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to quality evaluation and lowering healthcare costs
Mar 20, 2024 11:15 am ET
My Quest Story - Eddy Hurst
NORTHAMPTON, MA / ACCESSWIRE / March 20, 2024 / Quest Diagnostics
Mar 14, 2024 01:20 pm ET
Quest Colleague Is Exhibiting Care for Every Patient in Her Chair
NORTHAMPTON, MA / ACCESSWIRE / March 14, 2024 / Quest Diagnostics:
Mar 06, 2024 01:45 pm ET
Phlebotomist's Actions Keep One Patient Coming Back
NORTHAMPTON, MA / ACCESSWIRE / March 6, 2024 / A patient who goes often to a Patient Service Center (PSC) in Southern California had a special compliment for a colleague who's been at Quest for nearly 2 decades.
Mar 05, 2024 12:15 pm ET
My Quest Story - Allan Mendez
NORTHAMPTON, MA / ACCESSWIRE / March 5, 2024 / A chance encounter at a previous job put me on the right path.
Mar 04, 2024 02:45 pm ET
First PFAS "Forever Chemicals" Consumer-Initiated Blood Test With Physician Consult Launches on questhealth.com
SECAUCUS, NJ / ACCESSWIRE / March 4, 2024 / Quest Diagnostics (NYSE:DGX), the world's leader in diagnostic information services, announced the availability of the first consumer-initiated, physician-ordered blood-draw test for PFAS chemicals with the option to confer over the phone with a physician about the results.
Feb 29, 2024 01:45 pm ET
On Rare Disease Day, Q4HE Collaboration Highlights Purpose in Action
NORTHAMPTON, MA / ACCESSWIRE / February 29, 2024 / Quest Diagnostics
Feb 27, 2024 02:30 pm ET
Ten Years Running: FORTUNE Names Quest Diagnostics One of 2024 "World's Most Admired Companies"
SECAUCUS, NJ / ACCESSWIRE / February 27, 2024 / Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year.
Feb 23, 2024 11:30 am ET
Living Our Purpose - Ivelisse Lugo
Living our Purpose: This Patient Services colleague left an impression on a Quest patient of 30 years
Feb 23, 2024 08:35 am ET
Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
SECAUCUS, N.J., Feb. 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024, at 10:15 a.m. Eastern Time.
Feb 21, 2024 12:00 pm ET
Quest Diagnostics and Instacart Collaborate To Reduce Food Insecurity Across the United States With Integrated Patient Health Coaching and Nutritious Grocery Delivery
Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health Impacting Care
Feb 21, 2024 06:58 am ET
Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health Impacting Care
Feb 15, 2024 05:00 am ET
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
–  Roche led the financing alongside existing and new investors – 
Feb 13, 2024 07:07 am ET
Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer
Feb 12, 2024 07:01 am ET
First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com
Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified by National Academies of Sciences, Engineering, and MedicineOrganizations interested in workforce, community, and research population testing may also access the testSECAUCUS, N.J., Feb. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leader in diagnostic information services, today announced the availability of the first consumer-initiated, physician-ordered blood-draw test for PFAS chemicals with the option to confer over the phone with a physician abo
Feb 01, 2024 05:45 am ET
Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
Fourth quarter revenues of $2.29 billion, down 1.9% from 2022Fourth quarter reported diluted earnings per share ("EPS") of $1.70, up 95.4% from 2022; and adjusted diluted EPS of $2.15, up 8.6% from 2022Fourth quarter base business revenues of $2.25 billion, up 4.7% from 2022Fourth quarter COVID-19 testing revenues of $37 million, down 79.8% from 2022Full year revenues of $9.25 billion, down 6.4% from 2022Full year reported diluted EPS of $7.49, down 6.0% from 2022; and adjusted diluted EPS of $8.71, down 12.5% from 2022Full year base business revenues of $9.03 billion, up 7.1% from 2022Full
Jan 31, 2024 01:50 pm ET
Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"
SECAUCUS, N.J., Jan. 31, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year. 
Jan 29, 2024 12:45 pm ET
Fitbit and Quest Diagnostics Collaborate To Advance Research on the Use of Wearable Devices To Improve Metabolic Health
Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health
Jan 22, 2024 07:07 am ET
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic ch
BALTIMORE, Jan. 22, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist. SD-101 is delivered via hepatic arterial infusion or pancreatic retrograde venous infusion in their phase 1 and 1b clinical trials using their proprietary Pressure-
Jan 17, 2024 08:35 am ET
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024
SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 1, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.   
Jan 17, 2024 07:58 am ET
Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health
Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health
Jan 09, 2024 08:05 am ET
Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and
Jan 08, 2024 07:56 am ET
Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System
Transaction to broaden access to innovative, quality diagnostic information services for providers and patients
Jan 08, 2024 06:07 am ET
Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC
BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT's interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer (NSCLC). The AFT-57 clinical study is supported by Genentech, a member of the Roche Group, and will explore the efficacy and safety of an
Jan 04, 2024 10:00 am ET
No-Cost Testing Helps Bolster I-HEAL Community Wellness Day in Mississippi Delta Region
NORTHAMPTON, MA / ACCESSWIRE / January 4, 2024 / Quest Diagnostics recently provided no-cost Blueprint for Wellness® testing to more than 100 local community members who attended a wellness day in the Mississippi Delta region. The ninth annual I-HEAL Community Wellness Day, hosted by Quest for Health Equity (Q4HE) grantee Glenn Family Foundation, provided a host of no-cost resources for local families, including health screenings, nutritious food, mental health resources, vaccines, cleaning supplies, diapers, and more.
Dec 21, 2023 12:04 pm ET
Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference
SECAUCUS, N.J., Dec. 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:45 p.m. Eastern Time.
Dec 20, 2023 06:34 am ET
Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer
Seasoned healthcare executive and oncologist joins Executive Leadership Team
Dec 19, 2023 10:45 am ET
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology
Dec 19, 2023 07:54 am ET
Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel
Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis
Dec 18, 2023 10:30 am ET
Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation’s Corporate Equality Index for Seventh Consecutive Year
SECAUCUS, NJ / ACCESSWIRE / December 18, 2023 / Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that for the seventh straight year it has received a score of 100% on the Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index (CEI), the nation's foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.
Dec 14, 2023 07:53 am ET
Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer
BALTIMORE, Dec. 14, 2023 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology's industry-leading personalized MRD technology (Haystack MRD™) to help evaluate therapeutic response and provide molecular insights for a Rutgers Cancer Institute clinical trial examining early-stage triple-negative breast cancer (TNBC) patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin. Rutgers Cancer Institute together with RWJBarnabas Health is
Dec 13, 2023 03:15 pm ET
Quest Diagnostics Multi-Pronged Approach to Waste Reduction
NORTHAMPTON, MA / ACCESSWIRE / December 13, 2023 / Quest Diagnostics Originally published in Quest Diagnostics Corporate Responsibility Report 2022
Dec 11, 2023 10:15 am ET
New Report From Quest Diagnostics Unveils Priorities for Community Health Centers
NORTHAMPTON, MA / ACCESSWIRE / December 11, 2023 / Quest Diagnostics
Dec 07, 2023 01:50 pm ET
Universal DX Announces Strategic Collaboration With Quest Diagnostics To Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
UDX also announces the initial closing of its series B financing of approximately $70 million with investors, including Quest Diagnostics
Dec 07, 2023 07:01 am ET
Quest Diagnostics and CDC Expand Public Health Research Collaboration to Better Understand Hepatitis C Burden in the United States
Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C
Dec 06, 2023 08:04 am ET
Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index for Seventh Consecutive Year
SECAUCUS, N.J., Dec. 6, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that for the seventh straight year it has received a score of 100% on the Human Rights Campaign Foundation's 2022-2024 Corporate Equality Index (CEI), the nation's foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.
Dec 05, 2023 02:30 pm ET
ISO Standardization & Climate Action at Quest Diagnostics
NORTHAMPTON, MA / ACCESSWIRE / December 5, 2023 / Quest Diagnostics
Nov 28, 2023 09:30 am ET
Quest Volunteers Bring Treats, No Tricks, to Ronald McDonald House New York
NORTHAMPTON, MA / ACCESSWIRE / November 28, 2023 / Quest volunteers recently served lunch to children and families battling pediatric cancer and other serious illnesses at Ronald McDonald House New York, in collaboration with Quest for Health Equity (Q4HE) and Sesame Workshop.
Nov 28, 2023 07:40 am ET
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology
Nov 27, 2023 12:45 pm ET
Community Engagement at Quest Diagnostics
NORTHAMPTON, MA / ACCESSWIRE / November 27, 2023 / Quest Diagnostics
Nov 21, 2023 11:15 am ET
Quest Diagnostics Approach to Patient- and Consumer-Centered Care
NORTHAMPTON, MA / ACCESSWIRE / November 21, 2023 / Quest Diagnostics
Nov 20, 2023 07:52 am ET
Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
UDX also announces the initial closing of its series B financing of approximately $70 million with investors, including Quest Diagnostics
Nov 15, 2023 01:30 pm ET
Supply Chain Management at Quest Diagnostics
NORTHAMPTON, MA / ACCESSWIRE / November 15, 2023 / Quest Diagnostics
Nov 13, 2023 05:00 pm ET
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., Nov. 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share, payable on January 31, 2024 to shareholders of record of Quest Diagnostics common stock on January 17, 2024.
Nov 13, 2023 02:30 pm ET
Our Work Is Helping Quest Land on Some Noteworthy Lists
NORTHAMPTON, MA / ACCESSWIRE / November 13, 2023 / Quest Diagnostics
Nov 09, 2023 03:30 pm ET
Corporate Responsibility, Governance, and Ethics at Quest Diagnostics
NORTHAMPTON, MA / ACCESSWIRE / November 9, 2023 / Quest Diagnostics
Nov 09, 2023 07:45 am ET
Quest Diagnostics Launches Mobile Phlebotomy Service, Enabling Convenient At-Home Specimen Collection in the United States
Quest Mobile™ has 5,000 trained mobile phlebotomists whose reach will extend to 44 states by the end of 2023
Nov 08, 2023 09:15 am ET
Quest Diagnostics Recognized for Commitment to Closing Boardroom Gender Gap
NORTHAMPTON, MA / ACCESSWIRE / November 8, 2023 / Quest Diagnostics
Nov 06, 2023 11:55 am ET
Quest for Health Equity 2023 Summer Intern Spotlights
NORTHAMPTON, MA / ACCESSWIRE / November 6, 2023 / Quest Diagnostics:
Nov 01, 2023 12:15 pm ET
Developing and Retaining Talent at Quest Diagnostics
NORTHAMPTON, MA / ACCESSWIRE / November 1, 2023 / Quest Diagnostics
Oct 30, 2023 04:50 pm ET
Quest Diagnostics Prices $750 Million of Senior Notes
SECAUCUS, N.J., Oct. 30, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $750 million aggregate principal amount of its 6.400% senior notes due 2033 under Quest Diagnostics' shelf registration statement. 
Oct 25, 2023 07:00 am ET
Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer's Disease Prognostic Technology
—Quest to Develop and Market a Lab-developed Test Based on the IP of AlzoSure Predict® in the United States, Extending its Industry-leading Portfolio of Alzheimer's Disease Blood Tests—
Oct 24, 2023 10:45 am ET
Creating a Positive Employee Experience Based on the Quest Way
NORTHAMPTON, MA / ACCESSWIRE / October 24, 2023 / Quest Diagnostics
Oct 24, 2023 06:45 am ET
Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
Third quarter revenues of $2.30 billion, down 7.7% from 2022Third quarter reported diluted earnings per share ("EPS") of $1.96, down 9.7% from 2022; and adjusted diluted EPS of $2.22, down 5.9% from 2022Third quarter base business revenues of $2.27 billion, up 4.6% from 2022Full year 2023 revenues now expected to be between $9.19 billion and $9.24 billion; reported diluted EPS now expected to be between $7.61 and $7.71; and adjusted diluted EPS expected to be between $8.65 and $8.75SECAUCUS, N.J., Oct. 24, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading p
Oct 12, 2023 10:10 am ET
Think Pink: Quest Supports Women’s Breast & Heart Initiative’s National Pink Day Wellness Event
NORTHAMPTON, MA / ACCESSWIRE / October 12, 2023 / Quest Diagnostics
Oct 11, 2023 01:55 pm ET
Expanding Healthcare Access and Affordability at Quest Diagnostics
NORTHAMPTON, MA / ACCESSWIRE / October 11, 2023 / Quest Diagnostics:
Oct 05, 2023 06:12 pm ET
Neway Forms Lab Services Agreement with Quest Diagnostics to Speed Quality ESRD Testing
Relationship features use of Quest's distributed network of labs to deliver fast testing times in local communities around the United States
Oct 04, 2023 10:05 am ET
Quest Diagnostics to Release Third Quarter 2023 Financial Results on October 24, 2023
SECAUCUS, N.J., Oct. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2023 financial results on Tuesday, October 24, 2023, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.  
Oct 03, 2023 12:50 pm ET
Working Together To Create a Healthier World, One Life at a Time
NORTHAMPTON, MA / ACCESSWIRE / October 3, 2023 / Quest Diagnostics
Sep 13, 2023 10:15 am ET
Americares and Quest Diagnostics Expand Collaboration to Support Health Equity
STAMFORD, CT / ACCESSWIRE / September 13, 2023 / Americares and Quest Diagnostics, with the Quest Diagnostics Foundation, are teaming up to provide no-cost diagnostic services and expanded telehealth services to free and charitable clinics across the United States to reduce health disparities in underserved communities.
Sep 07, 2023 10:00 am ET
Quest Diagnostics Releases 2022 Corporate Responsibility Report
SECAUCUS, NJ / ACCESSWIRE / September 7, 2023 / Quest Diagnostics (NYSE:DGX), the leader in diagnostic information services, today released its 2022 Corporate Responsibility Report.
Sep 06, 2023 11:00 am ET
Rutgers University and Quest Diagnostics Double H.O.P.E. Clinic Capacity With Expanded Collaboration
NORTHAMPTON, MA / ACCESSWIRE / September 6, 2023 / Rutgers University and Quest Diagnostics are expanding their collaboration to further improve access to critical primary care services for uninsured and underinsured patients of the university's Health Outreach Practice Experience (H.O.P.E.) Clinic in Plainfield, NJ.
Aug 28, 2023 10:35 am ET
Aug 02, 2023 08:47 am ET
Inflammation Marker Signifies Increased Mortality Risk, Finds New Study in PLOS ONE
Ten-fold increase in death risk in individuals with high levels of myeloperoxidase, or MPO, compared to those with low levels, according to analysis of 3,700 patients of MDVIP tested by Quest Diagnostics
Jul 31, 2023 07:08 am ET
Quest Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com
AD-Detect™ Test for Alzheimer's Disease is the first blood-based biomarker test for assessing beta amyloid protein, a recognized marker of Alzheimer's disease, available for consumer purchase to help individuals identify their risk of developing Alzheimer's disease
Jul 26, 2023 06:45 am ET
Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
Second quarter revenues of $2.34 billion, down 4.7% from 2022Second quarter reported diluted earnings per share ("EPS") of $2.05, up 4.6% from 2022; and adjusted diluted EPS of $2.30, down 2.5% from 2022Second quarter base business revenues of $2.30 billion, up 9.5% from 2022Full year 2023 revenues now expected to be between $9.12 billion and $9.22 billion; reported diluted EPS now expected to be between $7.52 and $7.92; and adjusted diluted EPS expected to be between $8.50 and $8.90SECAUCUS, N.J., July 26, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading
Jul 20, 2023 01:15 pm ET
Q4HE Collaborates With Western University of Health Sciences To Support Biopsies Save Lives
NORTHAMPTON, MA / ACCESSWIRE / July 20, 2023 / Quest Diagnostics, through the Quest for Health Equity (Q4HE) initiative, has teamed up with Western University of Health Sciences (WesternU) to offer no-cost diagnostic testing services to support Biopsies Save Lives. This multidisciplinary program will offer no-cost testing to patients in Southern California who are low-income, uninsured, and underinsured and who have rare erosi
Jul 17, 2023 12:40 pm ET
Quest Diagnostics Named a 'Best Place To Work for Disability Inclusion' for Sixth Consecutive Year
SECAUCUS, NJ / ACCESSWIRE / July 17, 2023 / Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2023 Disability Equality Index® (DEI) Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD).
Jul 13, 2023 02:20 pm ET
Quest Diagnostics Employees Support Healthy NewsWorks Student Journalists
NORTHAMPTON, MA / ACCESSWIRE / July 13, 2023 / On May 23, several Quest Diagnostics employees volunteered at the Healthy NewsWorks Spring Celebration, featuring achievements of its student reporters from the greater Philadelphia area.
Jul 13, 2023 08:45 am ET
Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading
Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer
Jul 13, 2023 06:45 am ET
Quest Diagnostics Named a 'Best Place to Work for Disability Inclusion' for Sixth Consecutive Year
SECAUCUS, N.J., July 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2023 Disability Equality Index® (DEI) Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD).
Jul 11, 2023 07:08 am ET
Quest Launches Consumer-Initiated Genetic Test on questhealth.com to Deliver Personalized, Actionable Health Risk Insights
First consumer genetic health test under the Quest brand provides insights based on DNA, with unique features that include next-generation sequencing, robust support services, physician ordering, and access to one-on-one genetic counseling
Jul 10, 2023 07:30 am ET
Analysis of Half a Billion Lipid Tests from Five Continents Reveals Wide Variation of Lipid-Associated Risk of Heart Disease by Country and Sex
Organized by nine laboratories on five continents, the study by some members of the Global Diagnostics Network, a Quest Diagnostics-led strategic working group, is the largest to evaluate worldwide variability in cholesterol and triglyceride test results
Jul 06, 2023 08:07 am ET
Quest and Proov Collaborate to Bring Novel Home Fertility Test to Women Through questhealth.com
First and only FDA-cleared PdG (progesterone metabolite) home test to help confirm successful ovulation
Jun 27, 2023 01:20 pm ET
Inclusion in Action: Clifton and West Hills Labs
NORTHAMPTON, MA / ACCESSWIRE / June 27, 2023 / Quest Diagnostics
Jun 21, 2023 10:00 am ET
Quest Diagnostics to Release Second Quarter 2023 Financial Results on July 26, 2023
SECAUCUS, N.J., June 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2023 financial results on Wednesday, July 26, 2023, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.   
Jun 21, 2023 08:05 am ET
Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio
SECAUCUS, N.J., June 21, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of Haystack Oncology.
Jun 19, 2023 03:15 pm ET
New Tests Yield Actionable Insights
NORTHAMPTON, MA / ACCESSWIRE / June 19, 2023 / Quest Diagnostics
Jun 15, 2023 02:15 pm ET
Q4HE Teams Up With Experience Camps To Help Children Work Through Grief
NORTHAMPTON, MA / ACCESSWIRE / June 15, 2023 / Quest Diagnostics
Jun 13, 2023 11:45 am ET
Environmental Sustainability Drives Operational Excellence
NORTHAMPTON, MA / ACCESSWIRE / June 13, 2023 / Quest Diagnostics
Jun 09, 2023 11:45 am ET
Quest Diagnostics Elects Luis A. Diaz, Jr., M.D. to Its Board, Expanding the Number of Directors to 10
SECAUCUS, NJ / ACCESSWIRE / June 9, 2023 / Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, recently announced that its Board of Directors has elected Luis A. Diaz, Jr., M.D. to serve as a director. Including Dr. Diaz, the company's Board has 10 members. Dr. Diaz, 52, has been Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center since December 2016. Previously, he was a faculty member and physician at the Johns Hopkins University School of Medicine. He has founded several biotechnology
Jun 07, 2023 01:00 pm ET
Integrity: A Fundamental Value
NORTHAMPTON, MA / ACCESSWIRE / June 7, 2023 / Quest's vision is to empower better health through diagnostic insights. Our ability to achieve that vision is dependent on one of our key values, integrity. We strive to operate ethically, honestly, and responsibly, in accordance with our Code of Ethics.
Jun 02, 2023 11:19 am ET
Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference
SECAUCUS, N.J., June 2, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Global Healthcare Conference. Jim Davis, Chairman, CEO and President, will discuss recent market developments and trends as well as the company's performance and strategy. The presentation is scheduled for Thursday, June 8, 2023, at 2:30 p.m. Eastern Time.
Jun 01, 2023 01:15 pm ET
Wherever We Are, Quest Is Part of the Community
NORTHAMPTON, MA / ACCESSWIRE / June 1, 2023 / The corporate giving program at Quest captures the passion and commitment of our employees, leadership, and business partners to make lasting, meaningful contributions in the communities where we live and operate.
Jun 01, 2023 10:00 am ET
Quest Diagnostics to Speak at the William Blair 43rd Annual Growth Stock Conference
SECAUCUS, N.J., June 1, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 43rd Annual Growth Stock Conference. Sam Samad, Executive Vice President and CFO will discuss recent market developments and trends as well as the company's performance and strategy. The presentation is scheduled for Tuesday, June 6, 2023, at 4:20 p.m. Eastern Time.
May 24, 2023 02:45 pm ET
Inclusion and Diversity Council Inspires New and Ongoing Initiatives
NORTHAMPTON, MA / ACCESSWIRE / May 24, 2023 / Quest Diagnostics
May 23, 2023 01:15 pm ET
Quest’s Chicagoland Laboratory Hosts Americares Leaders During Lab Week
NORTHAMPTON, MA / ACCESSWIRE / May 23, 2023 / Quest Diagnostics is proud to support Americares in their efforts to improve health for people affected by poverty or disaster with a grant from Quest for Health Equity (Q4HE).
May 18, 2023 06:57 am ET
Post-Accident Workforce Drug Positivity for Marijuana Reached 25-Year High in 2022, Quest Diagnostics Drug Testing Index Analysis Finds
Increase Seen in the General U.S. Workforce Started Same Year First States Legalized Recreational Marijuana
May 17, 2023 04:05 pm ET
Quest Diagnostics Elects Luis A. Diaz, Jr., M.D. to its Board, Expanding the Number of Directors to 10
SECAUCUS, N.J., May 17, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Luis A. Diaz, Jr., M.D. to serve as a director.  Including Dr. Diaz, the company's Board has 10 members.Dr. Diaz, 52, has been Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center since December 2016. Previously, he was a faculty member and physician at the Johns Hopkins University School of Medicine. He has founded several biotechnology companies, including Epitop
May 17, 2023 10:35 am ET
Q4HE Grantee, American Heart Association, Celebrates Hispanic and Black Scholars
NORTHAMPTON, MA / ACCESSWIRE / May 17, 2023 / Quest Diagnostics:
May 16, 2023 04:15 pm ET
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., May 16, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share, payable on July 25, 2023 to shareholders of record of Quest Diagnostics common stock on July 11, 2023.
May 16, 2023 01:00 pm ET
Bringing Our Whole Selves To Work
NORTHAMPTON, MA / ACCESSWIRE / May 16, 2023 / Quest Diagnostics
May 10, 2023 10:15 am ET
Quest’s State-of-the-Art Laboratory in Clifton, NJ Hosts American Heart Association’s Hispanic Serving Institutions Scholars Program
NORTHAMPTON, MA / ACCESSWIRE / May 10, 2023 / Quest Diagnostics Incorporated, through the Quest Diagnostics Foundation, is proud to support the American Heart Association (AHA)'s Hispanic Serving Institutions (HSI) Scholars Program for the second year in a row.
May 08, 2023 11:35 am ET
Quest HealthConnect(TM): Personalized Access to Quality Healthcare
NORTHAMPTON, MA / ACCESSWIRE / May 8, 2023 / Quest Diagnostics:
May 04, 2023 07:00 am ET
Quest Diagnostics Extends Alzheimer's Disease Portfolio with New AI-Powered Test Service from uMETHOD Health
The collaboration aims to help physicians improve detection and care of potentially treatable causes of cognitive decline
May 02, 2023 10:10 am ET
Apr 27, 2023 06:44 am ET
Quest Diagnostics Reports First Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
First quarter revenues of $2.33 billion, down 10.7% from 2022First quarter reported diluted earnings per share ("EPS") of $1.78, down 39.0% from 2022; and adjusted diluted EPS of $2.04, down 36.6% from 2022First quarter base business revenues of $2.21 billion, up 10.0% from 2022Full year 2023 revenues now expected to be between $8.93 billion and $9.08 billion; reported diluted EPS now expected to be between $7.52 and $8.02; and adjusted diluted EPS expected to be between $8.45 and $8.95SECAUCUS, N.J., April 27, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's lead
Apr 27, 2023 06:34 am ET
Apr 26, 2023 12:10 pm ET
Safely Working Together
NORTHAMPTON, MA / ACCESSWIRE / April 26, 2023 / Quest Diagnostics
Apr 17, 2023 08:33 am ET
Quest Diagnostics and NewYork-Presbyterian Complete Laboratory Services Acquisition
SECAUCUS, N.J., April 17, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, and NewYork-Presbyterian, one of the nation's largest and most comprehensive academic medical centers, today announced that Quest has completed its previously announced acquisition of select assets of the laboratory services business of NewYork-Presbyterian. Financial details of the transaction were not disclosed.
Apr 12, 2023 10:55 am ET
Our Culture Rests on Equity in Compensation and Opportunity
NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Quest Diagnostics
Apr 10, 2023 02:20 pm ET
Quest Diagnostics' Purpose
NORTHAMPTON, MA / ACCESSWIRE / April 10, 2023 / "Our employees are united by our common purpose, which is: Working together to create a healthier world, one life at a time. They certainly brought our purpose to life during the pandemic and live it every day. Inspired by our employees, we recently introduced this new purpose, which serves as a compass for our business strategy evolution, growth, and culture." - Jim Davis, CEO and President, Quest Diagnostics.
Apr 06, 2023 01:30 pm ET
Quest Diagnostics Unveils Advanced Transplant Diagnostic Services Featuring Anywhere-Access in the United States
New capabilities include personalized patient access to Quest's national network of 2,100 patient service centers and 5,000 mobile and at-home phlebotomists, to support patient-compliant pre- and post-transplant testing and nationwide access, regardless of surgical center location
Apr 04, 2023 04:00 pm ET
Quest Diagnostics to Release First Quarter 2023 Financial Results on April 27, 2023
SECAUCUS, N.J., April 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2023 financial results on Thursday, April 27, 2023, before the market opens.  It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.   
Apr 04, 2023 11:45 am ET
Q4HE Aims To Improve Healthcare Access
NORTHAMPTON, MA / ACCESSWIRE / April 4, 2023 / Quest Diagnostics
Mar 29, 2023 10:15 am ET
The Los Angeles County Department of Public Health Joins Forces With Quest for Health Equity To Supply Blood Lead Testing at No Charge in the Exide Area
NORTHAMPTON, MA / ACCESSWIRE / March 29, 2023 / The Los Angeles County Department of Public Health (Public Health), with Quest for Health Equity (Q4HE), is providing laboratory blood lead testing at no charge to residents who may have been exposed to higher levels of lead and arsenic in communities surrounding the closed Exide battery recycling facility in Vernon, California.
Mar 22, 2023 08:58 am ET
Quest Diagnostics Unveils Advanced Transplant Diagnostic Services Featuring Anywhere-Access in the United States
New capabilities include personalized patient access to Quest's national network of 2,100 patient service centers and 5,000 mobile and at-home phlebotomists, to support patient-compliant pre- and post-transplant testing and nationwide access, regardless of surgical center location
Mar 21, 2023 09:05 am ET
First-of-Its-Kind Post-COVID-19 Panels Available at questhealth.com
New Panels Aimed at the Millions of Americans Still Suffering From COVID-19 Side Effects
Mar 20, 2023 08:40 am ET
Quest Diagnostics Completes Acquisition of Northern Light Laboratory in Maine
SECAUCUS, N.J., March 20, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of Northern Light Laboratory, the outreach laboratory services business of Northern Light Health, a large integrated healthcare system in Maine.
Mar 16, 2023 06:45 am ET
Quest Diagnostics to Discuss Strategic Priorities to Drive Growth and Create Shareholder Value at 2023 Investor Day
Updates 2023-26 compound annual growth rate (CAGR): Revenues expected to grow at mid single-digit rate; adjusted diluted earnings per share (EPS)* expected to grow at high single-digit rateRecommits to Invigorate savings and productivity improvements of approximately 3% annuallyGuidance for 2023 provided on February 2, 2023 remains unchangedSECAUCUS, N.J., March 16, 2023 /PRNewswire/ -- At a meeting with analysts and investors at its Investor Day, members of the executive leadership team of Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information ser
Feb 16, 2023 05:45 am ET
Quest Diagnostics Teams Up with Tower Health to Deliver High-Value, Innovative Laboratory Services
SECAUCUS, N.J. and WEST READING, Pa., Feb. 16, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Tower Health, a regional integrated healthcare system in Pennsylvania, are teaming up to enhance the quality and value of diagnostic services to patients and their doctors.
Feb 14, 2023 05:58 am ET
Quest Diagnostics and NewYork-Presbyterian Agree to Laboratory Services Transaction
Goal to serve NewYork-Presbyterian's providers and patients in the greater New York region and beyond
Feb 13, 2023 09:30 am ET
Quest Diagnostics to Host Investor Day on March 16, 2023
SECAUCUS, N.J., Feb. 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 16, 2023 at the New York Stock Exchange. 
Feb 02, 2023 05:45 am ET
QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2023
Fourth quarter revenues of $2.33 billion, down 15.0% from 2021Fourth quarter reported diluted earnings per share ("EPS") of $0.87, down 72.1% from 2021; and adjusted diluted EPS of $1.98, down 40.5% from 2021Fourth quarter base business revenues of $2.15 billion, up 6.3% from 2021Fourth quarter COVID-19 testing revenues of $184 million, down 74.6% from 2021Full year revenues of $9.88 billion, down 8.4% from 2021Full year reported diluted EPS of $7.97, down 48.7% from 2021; and adjusted diluted EPS of $9.95, down 30.1% from 2021Full year base business revenues of $8.43 billion, up 5.1% from 2
Feb 02, 2023 05:40 am ET
Quest Diagnostics Increases Dividend 7.6% To $0.71 Per Quarter; Announces $1 Billion Increase in Share Repurchase Authorization
SECAUCUS, N.J., Feb. 2, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the Company's Board of Directors has authorized a 7.6% increase in its quarterly dividend from $0.66 to $0.71 per share. The increase is effective with the dividend payable on April 24, 2023 to shareholders of record of Quest Diagnostics common stock on April 10, 2023. With the increase, the annual dividend will be $2.84 per share. The company has raised its dividend annually since 2011.
Feb 01, 2023 12:27 pm ET
FORTUNE Magazine Names Quest Diagnostics one of 2023 "World's Most Admired Companies" for Ninth Consecutive Year
SECAUCUS, N.J., Feb. 1, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2023 for the ninth consecutive year. 
Jan 23, 2023 08:05 am ET
More Americans Know Their Horoscope Sign Than Their Blood Type, Survey Reveals
Quest Launches the First Annual "Know Your Health" Survey to Inspire Americans to Take Control of Their Well-being in 2023
Jan 20, 2023 02:26 pm ET
Quest Diagnostics to Release Fourth Quarter and Full Year 2022 Financial Results on February 2, 2023
SECAUCUS, N.J., Jan. 20, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2022 financial results on Thursday, February 2, 2023, before the market opens.  It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. 
Jan 17, 2023 07:37 am ET
Pack Health to Expand in Birmingham to Accelerate Growth of Health Coaching Services Nationwide
Marks 1-Year since Quest Diagnostics Announced Plans to Acquire Pack Health to Extend Digital Engagement and Coaching Services to Health Plans, Employers and Life Sciences Companies
Jan 05, 2023 03:25 pm ET
Nationwide COVID-19 Testing Initiatives To Support Safer Classrooms
NORTHAMPTON, MA / ACCESSWIRE / January 5, 2023 / Quest Diagnostics
Jan 04, 2023 06:35 pm ET
Quest Provides No-Cost Testing During Community Wellness Day in Mississippi Delta Region
NORTHAMPTON, MA / ACCESSWIRE / January 4, 2023 / Glenn Family Foundation, a nonprofit whose mission is to improve life outcomes for children, youth, and families in the Mississippi Delta by erasing health inequities, recently hosted its 8th annual I-HEAL Community Wellness Day. The event provides community members with healthy food, an opportunity to learn skills such as hands-only CPR, and flu shots and health screenings at no cost.
Jan 04, 2023 01:28 pm ET
Quest Diagnostics to Speak at the 41st Annual J.P. Morgan Healthcare Conference
SECAUCUS, N.J., Jan. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 41st Annual J.P. Morgan Healthcare Conference. Jim Davis, CEO and President, and Sam Samad, Executive Vice President and CFO, will discuss the company's performance, and strategy, and the latest market developments and trends. The presentation is scheduled for Wednesday, January 11, 2023, at 10:30 a.m. Eastern Time.  
Dec 12, 2022 06:31 am ET
One in Two Patients Tested Misuse Prescription Drugs, Finds 10th Annual Quest Diagnostics Health Trends® Report
Analysis of 20 million clinical drug tests performed by Quest Diagnostics over the past decade shows increases in drug mixing and amphetamines use, and highlights the need for drug misuse prevention at the earliest stages of risk
Dec 08, 2022 03:07 pm ET
Quest Diagnostics and Northern Light Health Form Strategic Laboratory Collaboration to Improve Access to Affordable Diagnostic Services in Maine
Quest to acquire Northern Light Health's outreach laboratory business and professionally manage nine of its hospital laboratories
Dec 01, 2022 08:53 am ET
Sonora Quest Streamlines Access to At-Home Lab Services Through Getlabs Collaboration
Patient convenience improved by an easy-to-use scheduler for Getlabs in-home certified phlebotomy tests through Sonora Quest's website PHOENIX, Dec. 1, 2022 /PRNewswire/ -- Getlabs, the leader in providing nationwide infrastructure for remote health care delivery, and Sonora Quest Laboratories, Arizona's leading diagnostic testing laboratory, today announced that Getlabs' application programming interface (API) will be added to Sonora Quest's website. This integration allows patients to easily select and schedule an at-home sample collection when booking appointments through Sonora Quest's w
Dec 01, 2022 07:42 am ET
Quest Diagnostics Awarded Laboratory Stewardship Platform and Services Agreement with Premier, Inc.
SECAUCUS, N.J., Dec. 1, 2022  /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, has been awarded a group purchasing agreement for its laboratory stewardship solution with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company uniting an alliance of hospitals, health systems and providers.
Nov 28, 2022 08:25 am ET
Quest Diagnostics Completes Acquisition of Outreach Lab Services Business of Summa Health
Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Northeastern Ohio
Nov 16, 2022 09:02 am ET
ConferMED, through Grant from the Quest Diagnostics Foundation, now Providing Specialty eConsults to Front Line Primary Care Providers at Federally Qualified Health Centers in Five Key Metropolitan Ar
Close to 400,000 uninsured and underinsured patients served by participating FQHCs in Texas, Maryland, Massachusetts, Florida, and Illinois can now receive specialty care eConsults, saving time and money for patients and providers and improving health outcomes for underserved patients.
Nov 15, 2022 04:30 pm ET
DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today an agreement with
Nov 14, 2022 04:45 pm ET
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., Nov. 14, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share, payable on February 1, 2023 to shareholders of record of Quest Diagnostics common stock on January 18, 2023.
Nov 08, 2022 01:10 pm ET
Empowering Students To Create Better Health Outcomes Through School-Based Journalism
NORTHAMPTON, MA / ACCESSWIRE / November 8, 2022 / Quest Diagnostics
Nov 07, 2022 10:40 am ET
Quest Diagnostics Completes Leadership Succession as Jim Davis Becomes CEO and President, Joins Board of Directors
SECAUCUS, NJ / ACCESSWIRE / November 7, 2022 / Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that Jim Davis has succeeded Steve Rusckowski as the CEO and President of Quest Diagnostics, completing a transition first announced on February 3, 2022. In addition, Mr. Davis has been elected to the company's Board of Directors, expanding the board from nine to 10 directors.
Nov 04, 2022 10:50 am ET
Historically Black Colleges and Universities STEM Students Selected for Health Care Program
DALLAS, TX / ACCESSWIRE / November 4, 2022 / According to the Association of American Medical Colleges, only 8% of medical students and 5% of physicians are Black and African American. In an effort to address this disparity, the American Heart Association, the leading public health nonprofit organization dedicated to building a world of longer, healthier lives for all, has announced that 52 students from 23 academic institutions have been selected to participate in its Historically Black
Nov 04, 2022 08:05 am ET
Quest Introduces First of Its Kind Fitness Tests Built By and For Athletes on questhealth.com
SECAUCUS, N.J., Nov. 4, 2022 /PRNewswire/ --Quest Diagnostics (NYSE: DGX) has just unveiled three new fitness panels on questhealth.com, designed for athletes of every kind, from weekend warriors to gold medalists. Each fitness test panel provides a deep dive into an individual's health to paint a complete picture of overall fitness, including comprehensive tests that measure endurance, nutrition, energy, hydration, and hormone levels. It also informs on muscle and recovery status. This advanced fitness performance testing allows individuals to establish their fitness benchmark and find thei
Nov 03, 2022 09:25 am ET
Quest Diagnostics Named in Fast Company's Second Annual List of "Brands That Matter"
SECAUCUS, NJ / ACCESSWIRE / November 3, 2022 / Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, announced it has been named to the Fast Company second annual Brands That Matter list, honoring brands that communicate and demonstrate brand purpose. This list includes companies and nonprofits that have achieved relevance through cultural impact and social engagement, and authentically communicated their missions and ideals.
Nov 02, 2022 12:37 pm ET
Quest Diagnostics Named in Fast Company's Second Annual List of "Brands That Matter"
The recognition program honors companies and nonprofits providing people compelling reasons to care about them and offering inspiration for others to buy in 
Nov 02, 2022 11:10 am ET
Quest Donates 60 Laptops To Support Choose Healthy Life Community Health Workforce
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Choose Healthy Life (CHL) is a sustainable, scalable, and transferable approach to addressing public health disparities and inequities in the Black community by establishing a health workforce in the Black church. CHL began with 50 churches in 5 cities and expanded last year to 120 churches in 13 states and the District of Columbia. As a founding sponsor, the Quest Diagnostics Foundation provided financial support to establish CHL's church-based community health workforce.
Nov 01, 2022 09:45 am ET
Sesame Workshop and Quest Diagnostics Team Up to Address Health and Well-Being Inequities With Resources Connecting Parents and Healthcare Providers
NEW YORK, NY / ACCESSWIRE / November 1, 2022 / Sesame Workshop, the nonprofit educational organization behind Sesame Street which reaches 156 million children across more than 150 countries, and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a new nationwide program to address health and well-being inequities among young children, particularly in low-income, rural, and marginalized communities.
Nov 01, 2022 06:45 am ET
Oct 31, 2022 01:30 pm ET
Turning Classrooms Into Living Laboratories To Engage Students, Improve Nutrition, and Create Thriving Communities
NORTHAMPTON, MA / ACCESSWIRE / October 31, 2022 / Green Bronx Machine is an innovative, award-winning program that transforms hearts, minds, and futures by empowering students in low-income communities through learning experiences shaped by urban agriculture. Students and teachers work together to turn classrooms into agricultural laboratories where students grow their own plants and vegetables and watch as their seedlings become edible, nutritious, and delicious food. This indoor farming, which occurs in "tower gardens," is supplemented by engaging
Oct 28, 2022 09:45 am ET
Quest Diagnostics Attends St. Joseph's Health Foundation Gala
NORTHAMPTON, MA / ACCESSWIRE / October 28, 2022 / Quest Diagnostics
Oct 28, 2022 09:23 am ET
SAINT LOUIS UNIVERSITY TEAMS UP WITH QUEST DIAGNOSTICS ON ACCELERATED BACHELOR OF SCIENCE IN MEDICAL LABORATORY SCIENCE
Cutting-Edge Program to Help Fill the Dire Shortage of Behind-the-Scenes Heroes Who Perform Laboratory Testing that Informs Patient Diagnosis, Treatment
Oct 28, 2022 09:00 am ET
Oct 27, 2022 11:10 am ET
Reducing Barriers to Health Care: A Public-Private Solution
NORTHAMPTON, MA / ACCESSWIRE / October 27, 2022 / Rutgers University is teaming up with Quest Diagnostics to provide no-cost laboratory tests over the next year to diagnose and manage acute and chronic diseases for uninsured and underinsured patients of the university's H.O.P.E. Clinic in Plainfield, N.J.
Oct 27, 2022 09:00 am ET
Sesame Workshop and Quest Diagnostics Team Up to Address Health and Well-Being Inequities with Resources Connecting Parents and Healthcare Providers
NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Sesame Workshop, the nonprofit educational organization behind Sesame Street which reaches 156 million children across more than 150 countries, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a new nationwide program to address health and well-being inequities among young children, particularly in low-income, rural, and marginalized communities.
Oct 26, 2022 09:15 am ET
Q4HE Program Brings Indoor Gardening Curriculum to Ohio Food Desert
NORTHAMPTON, MA / ACCESSWIRE / October 26, 2022 / When one grows their own food, there is often a feeling of pride and accomplishment that comes along with it. The Quest Diagnostics Foundation and Green Bronx Machine are providing a group of children the opportunity to share in that experience with a donation of the Tower Gardens® aeroponic growing system for growing and harvesting their own food.
Oct 25, 2022 11:25 am ET
Key Insights on Current and Emerging Healthcare Issues
NORTHAMPTON, MA / ACCESSWIRE / October 25, 2022 / The Quest Diagnostics Health Trends® series of reports are drawn from our billions of data points to provide key insights into current healthcare issues. Health Trends reports in 2020 and 2021 have focused on important insights gained during the first years of the COVID-19 pandemic, including identifying significant declines in routine cancer screenings1 as well as in recommended screenings for Americans at high risk for other serious medical conditions, including hepatitis C (HCV),2 sexually transmit
Oct 20, 2022 06:45 am ET
Quest Diagnostics Reports Third Quarter 2022 Financial Results; Raises Guidance for Full Year 2022
Third quarter revenues of $2.49 billion, down 10.4% from 2021Third quarter reported diluted earnings per share ("EPS") of $2.17, down 46.0% from 2021; and adjusted diluted EPS of $2.36, down 40.4% from 2021Third quarter base business revenues of $2.17 billion, up 5.1% from 2021Full year 2022 reported diluted EPS now expected to be between $8.52 and $8.72; and adjusted diluted EPS expected to be between $9.75 and $9.95SECAUCUS, N.J., Oct. 20, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financ
Oct 19, 2022 01:15 pm ET
Reducing the Impact of COVID-19 in Underserved Communities in Illinois
NORTHAMPTON, MA / ACCESSWIRE / October 19, 2022 / Family Christian Health Center (FCHC) is a nonprofit FQHC providing health services to underserved populations in Harvey, IL, and broader Southland Illinois communities. Today, FCHC is working to expand access to COVID-19 testing and vaccinations while improving healthcare coordination to individuals in need. With Q4HE's support, FCHC is partnering with the faith-based community to expand awareness and education related to COVID-19 testing and vaccination, as well as chronic health-related issues.
Oct 18, 2022 08:45 am ET
Decode Health Collaborates with Quest Diagnostics to Speed Biomarker Discovery for Drug and Diagnostics Development
Features Nationally Scaled RNA Sequencing and Specimen Collection for Multiple Sclerosis and Non-Alcoholic Fatty Liver Disease with Plans to Expand
Oct 17, 2022 12:35 pm ET
Quest Diagnostics Aims to Close Gaps in Maternal Healthcare With New Obstetrics Test Panel That Includes Hepatitis C Screening
SECAUCUS, NJ / ACCESSWIRE / October 17, 2022 / Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, recently announced the launch of a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people easily and reliably for hepatitis C (HCV) with other laboratory tests typically ordered during early pregnancy.
Oct 14, 2022 10:15 am ET
Breast and Prostate Cancer Diagnoses Still Lagging During Second Full Year of COVID-19 Pandemic, Quest Diagnostics Health Trends(R) Study Finds
SECAUCUS, NJ / ACCESSWIRE / October 14, 2022 / More than two years after the COVID-19 pandemic began, diagnoses of breast and prostate cancer, two of the nation's leading causes of cancer death, continue to lag behind pre-pandemic levels, according to a nationally representative Quest Diagnostics Health Trends® study by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic infor
Oct 13, 2022 10:40 am ET
Thought Leadership Marries Insights to Influence
NORTHAMPTON, MA / ACCESSWIRE / October 13, 2022 / In addition to serving about half of hospitals and physicians and approximately 1 in 3 adults each year in the US, Quest Diagnostics has become a recognized thought leader and innovator in COVID-19 research and services. Our original research and critical insights are highlighting the many unanticipated impacts of the pandemic on public health.
Oct 13, 2022 08:30 am ET
Quest Encourages Consumers to "Put Your ____ To The Test" in Bold and Disruptive New Ad Campaign
SECAUCUS, N.J., Oct. 13, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic testing, unveiled a nationwide campaign, titled "Put Your ___ To The Test." The unexpected, provocative, and fresh campaign empowers consumers to take control of their health with more than 50 lab tests available for purchase directly from questhealth.com, quickly, conveniently, and confidentially, without a doctor's visit.
Oct 13, 2022 06:45 am ET
Quest Diagnostics Announces Organizational Changes to Accelerate Growth and Drive Operational Excellence
SECAUCUS, N.J., Oct. 13, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced Jim Davis, CEO-Elect, has made several organizational changes and leadership appointments of seasoned executives to better support the company's two-point business strategy to accelerate growth and drive operational excellence:
Oct 11, 2022 12:35 pm ET
Quest Spotlights Hispanic Employees' Cultural Traditions in Celebration of Hispanic Heritage Month
NORTHAMPTON, MA / ACCESSWIRE / October 11, 2022 / Quest Diagnostics
Oct 11, 2022 07:02 am ET
Breast and Prostate Cancer Diagnoses Still Lagging During Second Full Year of COVID-19 Pandemic, Quest Diagnostics Health Trends® Study Finds
Analysis of more than 1.1 million test results across the United States suggests more people are living with undiagnosed cancer than before the pandemic, with potential for worse outcomes and higher healthcare costs in the future
Oct 05, 2022 08:20 am ET
Quest Diagnostics to Acquire Outreach Lab Services Business of Summa Health
Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio
Sep 27, 2022 09:03 am ET
Quest Diagnostics to Release Third Quarter 2022 Financial Results on October 20, 2022
SECAUCUS, N.J., Sept. 27, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2022 financial results on Thursday, October 20, 2022, before the market opens.  It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
Sep 15, 2022 06:45 am ET
Quest Diagnostics Teams Up With Lee Health to Deliver High-Value, Innovative Laboratory Services
SECAUCUS, N.J. and FORT MYERS, Fla., Sept. 15, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Lee Health, Southwest Florida's primary community-owned health system, are teaming up to enhance the quality and value of diagnostic services to patients and their doctors.
Sep 14, 2022 09:00 am ET
Achievers and Quest Diagnostics Win Gold in the 2022 Brandon Hall Group Excellence Technology Awards
Achievers, an industry-leading employee experience software platform, announces its joint win of a Gold award by Brandon Hall Group with its customer case study of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.
Sep 14, 2022 08:00 am ET
Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease
CDPATH supports shared decision-making between patients and healthcare providers; provided at no cost to eligible adult patients who have not yet experienced serious complications*CAMBRIDGE, Mass., Sept. 14, 2022 /PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) today announced the national launch of the CDPATH™ program, which includes an innovative, validated personalized prognostic tool that uses blood tests† to help predict the potential risk of developing serious Crohn's disease-related complications within three years.1,2 CDPATH is available for use by US-based physicians and offered at no co
Sep 13, 2022 08:00 am ET
Hound Labs Forms Strategic Agreement with Quest Diagnostics
Hound Labs, a leader in ultra-sensitive, automated, accurate, and portable analytical technologies and creator of the HOUND® CANNABIS BREATHALYZER, today announces their agreement with Quest Diagnostics (NYSE: DGX), the world's leading provider of...
Sep 08, 2022 02:53 pm ET
Quest Diagnostics to Speak at the Morgan Stanley 20th Annual Global Healthcare Conference
SECAUCUS, N.J., Sept. 8, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley 20th Annual Global Healthcare Conference. Jim Davis, CEO-elect, and Sam Samad, Executive Vice President & CFO, will discuss the company's vision, goals, and capital deployment strategies.  The presentation is scheduled for Tuesday, September 13, 2022, at 4:40 p.m. Eastern Time.
Sep 07, 2022 07:16 pm ET
FDA Authorizes Quest Diagnostics' Proprietary Monkeypox Test for Emergency Use
First lab-developed test specifically designed to detect Monkeypox virus DNA to receive emergency use authorization during the monkeypox public health emergency
Sep 07, 2022 04:46 pm ET
uMETHOD Taps Getlabs to Deliver In-Home Diagnostics for Patients with Cognitive Decline
Precision medicine innovator uMETHOD now serves Arizona patients in-home; mobile draws in the Greater Phoenix area quadruple in the first month.On-demand remote lab collection supports patients and caregivers across the cognitive decline spectrum, including mild cognitive impairment, mild dementia, and mild Alzheimer's disease.PHOENIX, Sept. 7, 2022 /PRNewswire/ -- Remote healthcare delivery leader Getlabs and precision medicine for chronic conditions innovator uMETHOD today announced a partnership that makes Getlabs' at-home lab services available to all Arizona patients utilizing the Resto
Aug 17, 2022 07:30 am ET
Quest Diagnostics Aims to Close Gaps in Maternal Healthcare with New Obstetrics Test Panel that Includes Hepatitis C Screening
New test panel follows a Quest Diagnostics Health Trends® study with the CDC that revealed less than half of pregnant people are screened for hepatitis C as recommended under guidelines
Aug 10, 2022 05:05 pm ET
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., Aug. 10, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share, payable on October 19, 2022 to shareholders of record of Quest Diagnostics common stock on October 4, 2022.
Aug 04, 2022 07:00 am ET
QUEST DIAGNOSTICS BRIDGING ACCESS TO BETTER HEALTH FOR HISPANICS THROUGH ES TU PODER INITIATIVE
IRVING, Texas, Aug. 4, 2022 /PRNewswire/ -- Better healthcare among America's large and growing Hispanic community is receiving an important, new level of support from Quest Diagnostics, the world's leading provider of diagnostic information services, through the launch of a multi-faceted initiative.  "Es Tu Poder," being launched in San Antonio, Houston, Austin, Rio Grande Valley and other communities with large Hispanic populations in the Southwest, is designed to empower better health for Hispanics. The initiative includes the launch of a new microsite, Es Tu Poder, reminding patients tha
Jul 27, 2022 06:45 am ET
Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Fifth Consecutive Year
SECAUCUS, N.J., July 27, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2022 Disability Equality Index® (DEI) Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD). The Disability Equality Index® (DEI) is the world's most comprehensive benchmarking tool for the Fortune 1000 to measure disability workplace inclusion against competitors.
Jul 25, 2022 07:00 am ET
High Rates of Chronic Hepatitis B and Tuberculosis Co-Infection Observed in Nationally Representative Quest Diagnostics Study
Analysis of nearly 23 million lab tests finds only 1 in 3 patients with latent tuberculosis were also tested for chronic hepatitis B, despite similar risk factors in patients
Jul 21, 2022 06:45 am ET
Quest Diagnostics Reports Second Quarter 2022 Financial Results; Raises Guidance for Full Year 2022
Second quarter revenues of $2.45 billion, down 3.8% from 2021Second quarter reported diluted earnings per share ("EPS") of $1.96, down 60.5% from 2021; and adjusted diluted EPS of $2.36, down 25.8% from 2021Second quarter base business revenues of $2.10 billion, up 2.9% from 2021Full year 2022 reported diluted EPS now expected to be between $8.24 and $8.64; and adjusted diluted EPS expected to be between $9.55 and $9.95SECAUCUS, N.J., July 21, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today fina
Jul 19, 2022 09:00 am ET
Rite Aid and Quest Diagnostics Expand Access to COVID-19 PCR Testing Nationwide
Rite Aid (NYSE: RAD) today announced it is collaborating with Quest Diagnostics (NYSE: DGX) to provide access to quality, COVID-19 molecular testing (polymerase chain reaction or similar nucleic acid amplification test) to help Rite Aid customers detect and prevent the spread of COVID-19.
Jul 13, 2022 07:00 am ET
Quest Diagnostics Launches Monkeypox Virus Testing
Company to be able to perform approximately 30,000 tests a week by the end of July, supplementing public health response
Jul 11, 2022 06:45 am ET
Quest Diagnostics Releases 2021 Corporate Responsibility Report
SECAUCUS, N.J., July 11, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today released its 2021 Corporate Responsibility Report.
Jun 24, 2022 04:09 pm ET
Quest Diagnostics to Release Second Quarter 2022 Financial Results on July 21, 2022
SECAUCUS, N.J., June 24, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2022 financial results on Thursday, July 21, 2022, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
Jun 14, 2022 08:37 am ET
Pack Health Named Best Wellness Platform at Future Digital Awards by Juniper Research
Leading Patient Engagement Platform Honored in Digital Therapeutics and Mental Health Category
Jun 13, 2022 07:30 am ET
New Quest Diagnostics Health Trends® Study, in Collaboration with CDC, Shows Less Than Half of Pregnant People Screened for Hepatitis C
Nationally representative study of more than 5 million pregnant people finds those with Medicaid less likely to be screened than those with commercial insurance, demonstrating disparities in prenatal care
Jun 09, 2022 04:21 pm ET
Quest Diagnostics Names Sam Samad Executive Vice President and Chief Financial Officer
SECAUCUS, N.J., June 9, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that Sam Samad will become Executive Vice President and Chief Financial Officer. He will succeed Mark Guinan, who, in February, following eight and a half years in the role, announced his intention to retire. To provide a smooth transition, Mr. Guinan will remain at Quest through the report of second quarter financial results. Mr. Samad will join Quest Diagnostics on July 11, 2022. 
Jun 06, 2022 07:30 am ET
May 26, 2022 10:53 am ET
Quest Diagnostics to Speak at the Jefferies Healthcare Conference
SECAUCUS, N.J., May 26, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Healthcare Conference. Steve Rusckowski, Chairman, CEO and President and Jim Davis, CEO-elect, will discuss the company's vision, goals, and capital deployment strategies.  The presentation is scheduled for Friday, June 10, 2022, at 11:00 a.m. Eastern Time.
May 25, 2022 12:30 pm ET
Quest Diagnostics CHRO Receives "CHRO Lifetime Achievement Award"
SECAUCUS, N.J., May 25, 2022 /PRNewswire/ ---- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced Cecilia McKenney, Senior Vice President and Chief Human Resources Officer (CHRO), received the "CHRO Lifetime Achievement Award" by SharedXpertise Media, publishers of HRO Today magazine and HRO Today Global. 
May 17, 2022 04:52 pm ET
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., May 17, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share, payable on July 20, 2022 to shareholders of record of Quest Diagnostics common stock on July 6, 2022.
May 11, 2022 01:40 pm ET
Quest Diagnostics to Speak at the UBS 2022 Global Healthcare Conference
SECAUCUS, N.J., May 11, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the UBS 2022 Global Healthcare Conference. Steve Rusckowski, Chairman, CEO and President and Jim Davis, CEO-elect, will discuss the company's vision, goals, and capital deployment strategies.  The virtual presentation is scheduled for Tuesday, May 24, 2022, at 3:30 p.m. Eastern Time.
May 09, 2022 07:30 am ET
Survey of Human Resource Executives and Office Workers Suggests Employee Health May be a Key Ingredient to Addressing the "Great Resignation"
"2022 Health at Work" report from Quest Diagnostics reveals the attitudes and expectations of HR executive decision makers (HREs) and employees about the changing world of work, employee health and COVID-19, and what it takes to compete for today's scarcest resource–people
May 06, 2022 07:12 am ET
(DGX) News: Contact Leading Law Firm Johnson Fistel Regarding Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Quest Diagnostics Incorporated (“Quest” or the “Company”) (NYSE: DGX), any of its executive officers, or others violated federal securities laws by...
May 02, 2022 07:31 am ET
Physicians Foresee an Alzheimer's Disease Treatment Revolution Supported by Advanced Testing Tools, New Quest Diagnostics Report Finds
Blood Test for Early Detection of Alzheimer's Disease (AD) Risk Will Lead to Better Patient Care, Physicians Say; U.S. Adults Call for Earlier Evaluation and More Education
Apr 21, 2022 06:45 am ET
Quest Diagnostics Reports First Quarter 2022 Financial Results; Raises Guidance for Full Year 2022
First quarter revenues of $2.61 billion, down 4.0% from 2021First quarter reported diluted earnings per share ("EPS") of $2.92, down 15.6% from 2021; and adjusted diluted EPS of $3.22, down 14.4% from 2021Base business revenues of $2.01 billion, up 6.3% from 2021Full year 2022 reported diluted EPS now expected to be between $7.88 and $8.38; and adjusted diluted EPS expected to be between $9.00 and $9.50SECAUCUS, N.J., April 21, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results fo
Apr 20, 2022 04:10 pm ET
Quest Diagnostics Announces Organizational Changes to Accelerate Growth and Drive Operational Excellence
SECAUCUS, N.J., April 20, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has made several organizational changes and leadership appointments of seasoned executives to better support the company's two-point business strategy to accelerate growth and drive operational excellence:
Apr 04, 2022 08:55 am ET
Quest Diagnostics Adds Diabetic Retinopathy Screening Through its Patient Service Centers in Collaboration with IRIS
New Capability Enables Individuals Identified as High-Risk by Participating Health Plans to Access Screening through a Quest Diagnostics Site
Apr 01, 2022 07:32 am ET
(DGX) News: Contact Leading Law Firm Johnson Fistel Regarding Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Quest Diagnostics Incorporated (“Quest” or the “Company”) (NYSE: DGX), any of its executive officers, or others violated federal securities laws by...
Mar 30, 2022 09:09 am ET
Quest Diagnostics to Release First Quarter 2022 Financial Results on April 21, 2022
SECAUCUS, N.J., March 30, 2022  /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2022 financial results on Thursday, April 21, 2022, before the market opens.  It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. 
Mar 30, 2022 08:03 am ET
Workforce Drug Test Positivity Climbs to Highest Level in Two Decades, Finds Quest Diagnostics Drug Testing Index Analysis
Positivity for Cocaine and Marijuana Increase for Federally Mandated, Safety-Sensitive Workers Required to Test Under Federal Law

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.